Technical Analysis for 0Q1N - Pfizer Inc.

Grade Last Price % Change Price Change
F 25.40 -0.59% -0.15
0Q1N closed down 0.59 percent on Friday, April 26, 2024, on 6 percent of normal volume.
Earnings due: Apr 30
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
NR7 Range Contraction -0.59%
Narrow Range Bar Range Contraction -0.59%
Gapped Down Weakness -0.59%
Narrow Range Bar Range Contraction -2.68%
Gapped Down Weakness -2.68%
Narrow Range Bar Range Contraction -3.79%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Pfizer Inc. Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.


Classification

Is 0Q1N a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 41.2
52 Week Low 25.3
Average Volume 116,378
200-Day Moving Average 30.55
50-Day Moving Average 27.01
20-Day Moving Average 26.44
10-Day Moving Average 25.83
Average True Range 0.35
RSI (14) 36.31
ADX 21.65
+DI 28.68
-DI 52.23
Chandelier Exit (Long, 3 ATRs) 26.81
Chandelier Exit (Short, 3 ATRs) 26.35
Upper Bollinger Bands 28.02
Lower Bollinger Band 24.86
Percent B (%b) 0.17
BandWidth 11.94
MACD Line -0.44
MACD Signal Line -0.39
MACD Histogram -0.0502
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.42
Resistance 3 (R3) 25.42 25.41 25.41
Resistance 2 (R2) 25.41 25.41 25.41 25.41
Resistance 1 (R1) 25.41 25.41 25.41 25.41 25.41
Pivot Point 25.40 25.40 25.40 25.40 25.40
Support 1 (S1) 25.40 25.40 25.40 25.40 25.39
Support 2 (S2) 25.39 25.40 25.39 25.39
Support 3 (S3) 25.39 25.39 25.39
Support 4 (S4) 25.39